Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 8, 2026Liver CancerOpen Access

Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study

View Full Paper
Ask AI
Bookmark
Share

Authors

LYLin YeGLGuo-Xing LiuDYDa-Long Yang

Discussion

Loading...

Member takes

Overview

Multicenter retrospective study shows triple therapy improves survival and tumor response in unresectable HCC, suggesting significant benefits.

Key Points

  • To assess the efficacy and safety of triple therapy (TACE, lenvatinib, and PD-1 inhibitors) compared to dual therapy (TACE and lenvatinib) in conversion therapy for unresectable HCC.
  • Multicenter retrospective study at 20 Chinese tertiary hospitals
  • 289 patients received triple therapy, and 132 patients received dual therapy
  • Used inverse probability of treatment weighting to control for confounding variables.
  • TLP group had a higher objective response rate of 55.1% versus 34.7% (P < 0.001)
  • Median overall survival was 31.67 months in TLP vs. 25.00 months in TL (adjusted HR 0.60, 95% CI: 0.42-0.85, P = 0.001)
  • Median progression-free survival extended to 16.47 months in TLP versus 12.00 months in TL (adjusted HR 0.65, 95% CI: 0.47-0.93, P = 0.008).

Cite This Study

Ye et al. (2026) studied this question.

synapsesocial.com/papers/69fd7fcdbfa21ec5bbf085b3https://doi.org/10.1159/000552409
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study2026 · 13 citations
  2. 2Efficacy and safety of TACE plus lenvatinib with PD-1 inhibitor for unresectable huge hepatocellular carcinoma: a multicenter retrospective cohort study2025 · 8 citations
  3. 3TACE, lenvatinib, and PD-1 inhibitors in unresectable advanced hepatocellular carcinoma: an exploratory retrospective cohort study2026
  4. 4TACE plus lenvatinib and envafolimab for conversion therapy in unresectable HCC: a prospective pilot study2026
  5. 5The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study2024 · 7 citations